Secondary Adrenal Insufficiency: Causes, Symptoms, Diagnosis, and Treatment

What Is Secondary Adrenal Insufficiency?

Secondary adrenal insufficiency (SAI) is a failure of cortisol production caused by insufficient pituitary ACTH secretion, not by direct damage to the adrenal glands. The adrenals remain anatomically normal but functionally dormant without their hormonal driver. Cortisol controls blood pressure, glucose homeostasis, and the inflammatory response, so its absence can become a medical emergency within hours during physical stress.

The distinction from primary adrenal insufficiency matters clinically. In primary disease (Addison's disease), the adrenal cortex is destroyed, ACTH rises in a compensatory surge, and that elevated ACTH cross-reacts with melanocyte-stimulating hormone (MSH) receptors to produce the characteristic bronze skin hyperpigmentation. In SAI, ACTH is low, so hyperpigmentation is absent. Aldosterone production is also generally preserved in SAI because aldosterone regulation depends mainly on the renin-angiotensin system rather than ACTH, meaning patients with SAI rarely develop the severe sodium wasting and hyperkalemia seen in Addison's disease. [1]

The Endocrine Society's 2016 clinical practice guideline defines adrenal insufficiency as "an inadequate production of glucocorticoids with or without deficient mineralocorticoid secretion" and explicitly separates secondary (pituitary) from tertiary (hypothalamic) causes, though both are managed identically in practice. [2]

How Common Is Secondary Adrenal Insufficiency?

Prevalence estimates range from 150 to 280 per million people, making SAI more common than Addison's disease. Cross-sectional data from Germany showed a prevalence of 144 per million for primary and 280 per million for secondary and tertiary forms combined. [3]

The single largest driver of SAI is iatrogenic: patients prescribed glucocorticoids for asthma, rheumatoid arthritis, inflammatory bowel disease, or organ transplantation can develop hypothalamic-pituitary-adrenal (HPA) axis suppression within as little as 3 weeks of supraphysiologic steroid exposure. A 2020 systematic review in the Annals of Internal Medicine estimated that HPA-axis suppression occurs in approximately 49% of patients taking oral prednisolone at doses above 7.5 mg/day for more than 3 weeks. [4] When those steroids are stopped abruptly, the pituitary cannot immediately resume normal ACTH pulsatility, and cortisol output stays sub-therapeutic for weeks to months.

Pituitary adenomas and their surgical or radiation treatment account for the majority of non-iatrogenic SAI. Traumatic brain injury (TBI) is an underrecognized cause; a 2011 meta-analysis found that 16-17% of TBI survivors developed some degree of pituitary dysfunction, with ACTH deficiency present in roughly 8%. [5]

Causes and Risk Factors

Exogenous Glucocorticoid Suppression

Any route of glucocorticoid delivery carries suppression risk. Inhaled fluticasone at high doses (>1 to 000 mcg/day), intra-articular triamcinolone injections, topical betamethasone over large skin areas, and intranasal budesonide have all been documented to suppress the HPA axis. [4] The risk is proportional to dose, duration, and the potency of the specific molecule. Dexamethasone suppresses the axis more than equipotent doses of hydrocortisone because of its longer half-life.

Pituitary Tumors and Their Treatment

Non-functioning pituitary macroadenomas compress the corticotroph cells. Cushing's disease, paradoxically, causes post-surgical SAI: surgical removal of a cortisol-secreting pituitary adenoma leaves the remaining corticotrophs in a prolonged state of suppression because they have been chronically inhibited by high cortisol. Recovery of normal ACTH secretion after successful Cushing's disease surgery may take 6-18 months, during which full glucocorticoid replacement is required. [6]

Traumatic Brain Injury and Subarachnoid Hemorrhage

Shear injury to the pituitary stalk disrupts portal blood flow carrying hypothalamic releasing hormones to the anterior pituitary. Because symptoms overlap with TBI-related fatigue and depression, SAI in this population is commonly missed. Screening with a morning cortisol level at 3 months and 12 months post-injury is recommended by several neuroendocrinology societies. [5]

Infiltrative and Autoimmune Diseases

Sarcoidosis, lymphocytic hypophysitis (more common during or after pregnancy), histiocytosis X, and IgG4-related disease can all infiltrate the pituitary and reduce ACTH output. Lymphocytic hypophysitis in particular targets the posterior pituitary and pituitary stalk but can involve corticotrophs. Anti-PD-1 and anti-CTLA-4 immune checkpoint inhibitor therapies used in oncology cause hypophysitis in 0.5-17% of patients depending on agent and regimen. [7]

Symptoms of Secondary Adrenal Insufficiency

Symptoms of SAI are less dramatic at baseline than those of Addison's disease because aldosterone is intact, but they become dangerous under physiologic stress. The most common complaints are profound fatigue, generalized weakness, anorexia, nausea, and low-grade abdominal discomfort. Hypoglycemia occurs more readily in SAI than in primary disease because cortisol's role in gluconeogenesis is absent.

Postural dizziness without frank hypotension at rest is reported by many patients. Hyponatremia, caused by impaired free water excretion from high ADH levels (cortisol normally suppresses ADH), occurs in 30-40% of patients with SAI and may be the presenting laboratory finding. [2]

Weight loss is gradual, averaging 3-5 kg over several months in registry data. Depression and cognitive slowing are frequent complaints that delay diagnosis because they are attributed to psychiatric causes first. There is no hyperpigmentation and no salt craving; those features point toward primary adrenal insufficiency.

Diagnosing Secondary Adrenal Insufficiency

Diagnosis requires demonstrating inadequate cortisol production and then identifying a pituitary or hypothalamic cause.

Morning Serum Cortisol

A random cortisol drawn between 7:00 and 9:00 AM takes advantage of the normal diurnal peak. A value above 18 mcg/dL (500 nmol/L) makes SAI unlikely. A value below 3 mcg/dL is strongly diagnostic. Values in between require dynamic testing. [2]

The 250-mcg Cosyntropin Stimulation Test

Cosyntropin (synthetic ACTH 1-24) is injected intravenously or intramuscularly at 250 mcg; serum cortisol is measured at 0, 30, and 60 minutes. A peak cortisol <18 mcg/dL confirms adrenal insufficiency. The test is accurate for SAI of at least 4-6 weeks' duration because before that window the adrenal cortex has not yet atrophied enough to fail the test even when ACTH secretion is impaired. [2] The 1-mcg low-dose cosyntropin test is more sensitive for early or partial SAI but is not standardized across laboratories.

Plasma ACTH

A simultaneously drawn plasma ACTH level differentiates primary from secondary disease. In SAI, ACTH is low or inappropriately normal (below 20 pg/mL when cortisol is also low). In Addison's disease, ACTH exceeds 100 pg/mL and often exceeds 400 pg/mL. [1]

Insulin Tolerance Test

The insulin tolerance test (ITT) remains the reference standard for diagnosing SAI, particularly in the first 4-6 weeks after pituitary surgery before the adrenal cortex has atrophied. Hypoglycemia induced by 0.1 U/kg regular insulin activates the entire HPA axis. A peak cortisol <18 mcg/dL during symptomatic hypoglycemia confirms deficiency. The ITT is contraindicated in patients with seizure disorders, severe cardiovascular disease, or a baseline cortisol below 5 mcg/dL. [2]

MRI of the Pituitary

Once biochemical SAI is confirmed, contrast-enhanced MRI of the sella turcica with dedicated pituitary protocol is the imaging of choice to identify adenomas, stalk thickening, empty sella, or infiltrative disease. [6]

Secondary Adrenal Insufficiency vs. Addison's Disease: Key Differences

| Feature | Secondary AI | Addison's Disease (Primary AI) | |---|---|---| | ACTH level | Low or low-normal | High (>100 pg/mL) | | Aldosterone | Preserved | Deficient | | Hyperpigmentation | Absent | Present | | Hyponatremia | Possible (ADH-mediated) | Common (salt-wasting) | | Hyperkalemia | Absent | Common | | Main cause | Pituitary or hypothalamic dysfunction | Autoimmune adrenalitis (80% of cases) | | Fludrocortisone needed | Rarely | Yes, typically 50-100 mcg/day |

Cushing's disease (pituitary-driven cortisol excess) and Cushing's syndrome (any cause of cortisol excess) sit at the opposite end of the spectrum and can paradoxically produce SAI after treatment, as described above. [6]

Treatment: Hydrocortisone Replacement

Standard Daily Dosing

Hydrocortisone is the preferred replacement agent because its pharmacokinetics most closely mimic physiologic cortisol secretion. The Endocrine Society guideline recommends 15-25 mg/day divided into two or three doses, with the largest dose given in the morning to approximate the normal diurnal cortisol surge. [2] A common split is 10 mg on waking, 5 mg at noon, and 5 mg at 3:00-4:00 PM. Evening doses are avoided to preserve sleep quality.

Prednisone 3-5 mg/day or dexamethasone 0.25-0.5 mg/day at bedtime are alternatives used when adherence to multiple daily doses is problematic, though dexamethasone's long half-life makes dose titration less precise and carries a higher risk of over-replacement.

Over-replacement is not benign. Chronic supraphysiologic dosing produces iatrogenic Cushing's syndrome, including visceral adiposity, insulin resistance, osteoporosis, and cardiovascular risk. [3] Monitoring should include annual bone density scanning in patients receiving replacement therapy for more than 2 years.

Sick-Day Rules

The HealthRX clinical team uses the following stress-dosing framework, based on Endocrine Society guidance and adapted from the European Society of Endocrinology consensus statement on glucocorticoid replacement:

Tier 1 (mild illness: fever <38.5°C, nausea without vomiting): Double the daily hydrocortisone dose for the duration of the illness and return to baseline when symptoms resolve.

Tier 2 (moderate illness: fever >38.5°C, vomiting that prevents oral intake, or any planned surgical procedure under local anesthesia): Triple the daily dose, or administer hydrocortisone 50 mg intramuscularly if oral intake is impossible.

Tier 3 (major surgery or critical illness): Hydrocortisone 100 mg IV bolus at induction, followed by 200 mg per 24 hours as a continuous infusion or 50 mg every 6 hours; taper rapidly over 48-72 hours once the acute period passes.

Every patient should carry a steroid emergency card and a pre-filled hydrocortisone 100 mg IM injection kit (Solu-Cortef Act-O-Vial). [2]

Monitoring Adequacy of Replacement

Unlike thyroid hormone replacement, there is no single blood test that reliably confirms correct hydrocortisone dosing because cortisol is cleared within hours of each dose. Clinicians assess adequacy through symptom control, weight stability, electrolytes, and the absence of cushingoid features. Salivary cortisol day-curve profiles drawn at 0, 30, 60, and 120 minutes after the morning dose are gaining traction in specialist centers as a surrogate measure of exposure, though this approach remains outside most standard-of-care guidelines. [2]

Adrenal Crisis: Recognition and Emergency Management

Adrenal crisis is an acute, life-threatening deficiency of cortisol occurring under conditions of physiologic stress. Patients with SAI who are ill, injured, or undergoing surgery face a 6-8% per-patient per-year risk of adrenal crisis. A 2016 study of 883 patients with adrenal insufficiency at German centers reported a crisis rate of 8.3 per 100 patient-years and a crisis mortality of 6%. [8]

Symptoms include sudden severe weakness, hypotension, nausea, vomiting, abdominal pain, and altered mental status. Hyponatremia without hyperkalemia (because aldosterone is preserved in SAI) is the most common laboratory clue. Hypoglycemia may accompany the presentation.

Management requires immediate action: hydrocortisone 100 mg IV or IM as a stat dose, followed by 200 mg/24h continuous infusion or 50 mg every 6 hours. Aggressive IV isotonic saline (0.9% NaCl) at 1 L over the first hour corrects volume depletion. Blood glucose should be monitored every 1-2 hours. Fludrocortisone is not needed acutely because supraphysiologic hydrocortisone doses provide sufficient mineralocorticoid activity. [2]

Dr. Stefan Bornstein, lead author of the 2016 Endocrine Society adrenal insufficiency guideline, stated: "Patients with adrenal insufficiency and their families should be taught to recognize the symptoms of adrenal crisis and trained in the parenteral self-administration of hydrocortisone." [2]

Special Populations

Pregnancy

Cortisol requirements increase in the third trimester as cortisol-binding globulin rises. Hydrocortisone doses may need to be increased by 20-40% in the third trimester, and an IV hydrocortisone 100 mg bolus is standard at the onset of active labor. [2] Fetal outcomes are generally normal with appropriate replacement, but untreated SAI during pregnancy carries a high risk of maternal adrenal crisis.

Children and Adolescents

Children with SAI due to pituitary tumors or prior cranial irradiation require weight-based hydrocortisone dosing, typically 8-10 mg/m2/day. Growth hormone deficiency commonly co-exists and should be assessed concurrently because GH therapy can unmask sub-clinical adrenal insufficiency by accelerating cortisol clearance. [2]

Patients on Immune Checkpoint Inhibitors

Checkpoint inhibitor-induced hypophysitis can progress rapidly. A morning cortisol drawn before each infusion cycle is a practical screening step for patients on ipilimumab or combination PD-1/CTLA-4 regimens. [7] Once hypophysitis is confirmed, hydrocortisone replacement is started and the checkpoint inhibitor can often be continued because high-dose immunosuppression with corticosteroids does not reliably reverse the hypophysitis.

Glucocorticoid-Induced SAI: How to Taper Safely

Patients on long-term systemic glucocorticoids should never be abruptly discontinued. A supervised taper to physiologic replacement and then formal testing is the safe approach:

1. Reduce the supraphysiologic dose to an equivalent of prednisolone 5 mg/day (approximately hydrocortisone 20 mg/day) over 2-4 weeks, adjusting speed to disease activity.
2. Switch to hydrocortisone 20 mg in the morning for 4 weeks to allow diurnal rhythm to re-establish.
3. Check a 9 AM cortisol on the day after the previous morning dose. If cortisol exceeds 18 mcg/dL, tapering can continue.
4. Reduce hydrocortisone to 10 mg each morning for 4 more weeks, then repeat the 9 AM cortisol check.
5. If the 9 AM cortisol (off-dose for 18-24 hours) exceeds 18 mcg/dL, a formal cosyntropin test confirms recovery.

The full recovery of the HPA axis after prolonged glucocorticoid suppression may take 6-12 months. During that period, all sick-day rules apply. [4]

Differentiating SAI from "Adrenal Fatigue"

"Adrenal fatigue" is not a recognized medical diagnosis. The term circulates widely online to describe chronic tiredness attributed to overworked adrenal glands. Laboratory testing in people labeled with adrenal fatigue consistently shows normal morning cortisol and normal cosyntropin stimulation tests. The Endocrine Society issued a formal position statement in 2016 noting: "No scientific proof exists to support adrenal fatigue as a true medical condition." [2]

This distinction has real consequences. Patients who self-treat presumed adrenal fatigue with over-the-counter adrenal glandular supplements or low-dose hydrocortisone purchases from unregulated online pharmacies risk suppressing a previously normal HPA axis, creating the very condition they believed they had. Actual SAI requires biochemical confirmation before any steroid is prescribed.

Long-Term Outlook and Quality of Life

SAI is a lifelong condition in most non-iatrogenic cases, but a treatable one. Patients on optimized hydrocortisone replacement report persistent fatigue and reduced quality of life compared with age-matched controls. A 2012 study in the Journal of Clinical Endocrinology and Metabolism found that patients with adrenal insufficiency scored significantly lower on the SF-36 vitality subscale (mean score 44.2 vs. 57.8 in controls, P<0.001) even when biochemical replacement was considered adequate. [9]

Modified-release hydrocortisone (Plenadren, approved in Europe), which provides a single morning dose with a delayed-release tail, improved quality-of-life scores and HbA1c in a randomized crossover trial of 64 patients compared with conventional immediate-release tablets. [10] Plenadren is not FDA-approved in the United States as of early 2025, though once-daily modified-release formulations remain an active area of clinical development.

Patients should wear medical-alert identification (bracelet or card) at all times listing their diagnosis, their daily hydrocortisone dose, and emergency injection instructions. Annual follow-up with an endocrinologist for symptom review, bone density monitoring, and adjustment of the sick-day action plan reduces hospitalization rates. [2]